ClinicalTrials.Veeva

Menu

The Hospice Advanced Dementia Symptom Management and Quality of Life Trial (HAS-QOL)

NYU Langone Health logo

NYU Langone Health

Status

Completed

Conditions

Dementia

Treatments

Behavioral: Usual Care
Behavioral: Aliviado Dementia Care-Hospice Edition QAPI program

Study type

Interventional

Funder types

Other
NIH

Identifiers

NCT04175977
5R33AG061904-05 (U.S. NIH Grant/Contract)
19-01186

Details and patient eligibility

About

The Aliviado Dementia Care Program (formerly known as the Dementia Symptom Management at Home Program, or DSM-H) was developed to implement dementia friendly care for persons with Dementia and their caregivers living in the community. Aliviado Dementia Care-Hospice Edition is a systems level quality assurance performance improvement program that includes interdisciplinary team training, validated assessment instruments, patient-centered care plans, treatment algorithms for behavioral and psychological symptoms of dementia and terminal delirium, and caregiver education pamphlets. Utilizing the R61/R33 mechanism, the Aliviado Dementia Care-Hospice Edition was successfully implemented in 2 sequential pilot trials in the hospice setting in 2019 (R61 phase). Following the successful pilot trials and the attainment of the R61 milestones, the investigators now seek to test the effectiveness of Aliviado Dementia Care-Hospice Edition in a pragmatic RCT in 25 hospice agencies across the nation (R33 phase) on its ability to reduce antipsychotic use (primary outcome) and effect quality (secondary and exploratory outcomes).

Full description

As the population ages, the incidence rate of Alzheimer's Disease and Related Disorders (dementia) is expected to triple. The National Alzheimer's Plan recognizes that while the number of persons with dementia (PWD) is increasing substantially, the healthcare and long term care systems are unprepared to provide high quality, effective and efficient care to the PWD and their caregivers. PWD often have many behavioral and psychological symptoms of dementia (BPSD) including agitation, depression and sleep disturbances that affect both the quality of life (QOL) of the PWD and the caregiver. Unfortunately, due to a lack of programs to insert evidence-based care into the community, and hospice system specifically, PWD receive inappropriate and even harmful care. The investigators have developed the Aliviado Dementia Care Program (formerly known as the Dementia Symptom Management at Home Program, or DSM-H) to implement dementia friendly care for PWD and their caregivers in the community. Initially developed for use in home healthcare (HHC), the investigators have modified the program for use in hospice. The Aliviado Dementia Care-Hospice Edition is a systems level quality assurance performance improvement (QAPI) program that includes workforce training, and agency level workflow changes.

Enrollment

44,143 patients

Sex

All

Ages

18+ years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

Interdisciplinary Team (IDT) MEMBERS:

  • All English speaking IDT members
  • Employed or contracted by the participating agency who are receiving Aliviado Dementia Care-Hospice Edition online or champion training
  • All PWD (Persons with dementia) who are newly admitted to a participating hospice during the timeframe following implementation of the intervention who are over the age of 50 and have an ICD-10 code corresponding to a dementia diagnosis in their chart will be eligible.
  • Greater than 18 years of age

Exclusion criteria

IDT MEMBERS:

• IDT members who are per diem

Trial design

Primary purpose

Supportive Care

Allocation

Randomized

Interventional model

Sequential Assignment

Masking

Single Blind

44,143 participants in 8 patient groups

Wave 1: Usual Care for Months 1-7, Transition for Months 8-9, Intervention for Months 10-26
Experimental group
Description:
PWD at the hospice sites randomized to Wave 1 will receive usual care for 7 months, followed by the 2-month-long transition to the intervention over months 8 and 9, followed by the QAPI intervention for 16 Months from Month 10-26.
Treatment:
Behavioral: Aliviado Dementia Care-Hospice Edition QAPI program
Behavioral: Usual Care
Wave 2: Usual Care for Months 1-8, Transition for Months 9-10, Intervention for Months 11-26
Experimental group
Description:
PWD at the hospice sites randomized to Wave 2 will receive usual care for 8 months, followed by the 2-month-long transition to the intervention over months 9 and 10, followed by the QAPI intervention for 15 months from Month 11-26.
Treatment:
Behavioral: Aliviado Dementia Care-Hospice Edition QAPI program
Behavioral: Usual Care
Wave 3: Usual Care for Months 1-9, Transition for Months 10-11, Intervention for Months 12-26
Experimental group
Description:
PWD at the hospice sites randomized to Wave 3 will receive usual care for 9 months, followed by the 2-month-long transition to the intervention during months 10 and 11, followed by the QAPI intervention for 14 months from Months 12-26.
Treatment:
Behavioral: Aliviado Dementia Care-Hospice Edition QAPI program
Behavioral: Usual Care
Wave 4: Usual Care for Months 1-10, Transition for Months 11-12, Intervention for Months 13-26
Experimental group
Description:
PWD at the hospice sites randomized to Wave 4 will receive usual care for 10 months, followed by the 2-month-long transition to the intervention during months 11 and 12, followed by the QAPI intervention for 13 months from Months 13-26.
Treatment:
Behavioral: Aliviado Dementia Care-Hospice Edition QAPI program
Behavioral: Usual Care
Wave 5: Usual Care for Months 1-11, Transition for Months 12-13, Intervention for Months 14-26
Experimental group
Description:
PWD at the hospice sites randomized to Wave 5 will receive usual care for 11 months, followed by the 2-month-long transition to the intervention during months 12 and 13, followed by the QAPI intervention for 12 months from Months 14-26.
Treatment:
Behavioral: Aliviado Dementia Care-Hospice Edition QAPI program
Behavioral: Usual Care
Wave 6: Usual Care for Months 1-12, Transition for Months 13-14, Intervention for Months 15-26
Experimental group
Description:
PWD at the hospice sites randomized to Wave 6 will receive usual care for 12 months, followed by the 2-month-long transition to the intervention during months 13 and 14, followed by the QAPI intervention for 11 months from Months 15-26.
Treatment:
Behavioral: Aliviado Dementia Care-Hospice Edition QAPI program
Behavioral: Usual Care
Wave 7: Usual Care for Months 1-13, Transition for Months 14-15, Intervention for Months 16-26
Experimental group
Description:
PWD at the hospice sites randomized to Wave 7 will receive usual care for 13 months, followed by the 2-month-long transition to the intervention during months 14 and 15, followed by the QAPI intervention for 10 months from Months 16-26.
Treatment:
Behavioral: Aliviado Dementia Care-Hospice Edition QAPI program
Behavioral: Usual Care
Wave 8: Usual Care for Months 1-14, Transition for Months 15-16, Intervention for Months 17-26
Experimental group
Description:
PWD at the hospice sites randomized to Wave 7 will receive usual care for 14 months, followed by the 2-month-long transition to the intervention during months 15 and 16, followed by the QAPI intervention for 9 months from Months 17-26.
Treatment:
Behavioral: Aliviado Dementia Care-Hospice Edition QAPI program
Behavioral: Usual Care

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems